Drugs / Sodium butyrate
Sodium butyrate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06022588 | Mar → Apr 2021 | chronic intestinal vascular insufficiency | Erasmus Medical Center | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sodium butyrate | “Sodium butyrate, 1-13C, 99%, Cambridge Isotope Laboratories, Inc.USA” NCT06022588 ↗ |
| Known as | 13C-butyrate | “a solution containing butyrate of which 12C of the last 4 carbon positions of butyrate were replaced by 13C butyrate.” NCT06022588 ↗ |
| Known as | Butyric acid sodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL62381 ↗ |
| Known as | NSC-174280 | ChEMBL registry synonym — accepted as the source's own label CHEMBL62381 ↗ |
| Modality | Diagnostic / imaging agent | “Isotope labelled-butyrate and glucose breath testing could theoretically quantify mucosal oxygen consumption and thereby detect ischemia” NCT06022588 ↗ |
| Route | Oral | “receiving either oral 13C -butyrate or 13C -glucose” NCT06022588 ↗ |